logo

For the Inventor, By the Inventor

Omaha, NE, United States of America

Rongshi Li

This inventor holds 8 USPTO granted patents. Top assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., Chongqing Zein Pharmaceutical Co., Ltd, The Board of Regents of the University of Nebraska. Active years: 2016-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rongshi Li. Retrieved from https://idiyas.com/inventor/rongshi-li

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8

% Patents Active = 75.0

Average Co-Inventor Count = 3.6

ph-index = 1

Forward Citations = 5(Granted Patents)


Location History:

  • Tampa, FL (US) (2016)
  • Omaha, NE (US) (2016 - 2021)

Company Filing History:

goldMedal6 out of 312 
 
H. Lee Moffitt Cancer Center and Research Institute, Inc.
 patents
silverMedal3 out of 3 
 
Chongqing Zein Pharmaceutical Co., Ltd
 patents
bronzeMedal2 out of 969 
 
The Board of Regents of the University of Nebraska
 patents
where one patent can have more than one assignee

Years Active: 2016-2021

Loading Chart...
8 patents (USPTO):Explore Patents
1. 10954192 - Pyrrolomycins and methods of using the same (2021-03-23),
2. 10414725 - Pyrrolomycins and methods of using the same (2019-09-17),
3. 10358454 - Marinopyrrole derivatives and methods of making and using same (2019-07-23),
4. 9868747 - Marinopyrrole derivatives and methods of making and using same (2018-01-16),
5. 9808447 - Inhibitors of Rho associated protein kinases (ROCK) and methods of use (2017-11-07),
6. 9700044 - Symmetrical marinopyrrole derivatives as potential antibiotic agents (2017-07-11),
7. 9409868 - Inhibitors of rho associated protein kinases (ROCK) and methods of use (2016-08-09),
8. 9340501 - Marinopyrrole derivatives as anticancer agents (2016-05-17),

Title: The Innovative Contributions of Rongshi Li

Introduction

Rongshi Li is a prominent inventor based in Omaha, NE, known for his significant contributions to the field of pharmaceuticals. With a total of eight patents to his name, he has made remarkable strides in developing innovative solutions for treating infectious diseases and cancers.

Latest Patents

Among his latest patents are the pyrrolomycin derivatives, which are designed to modulate Mcl-1 and inhibit the proliferation of bacteria and pathogens. These derivatives hold promise for treating various infectious diseases and cancers, showcasing the potential impact of his work on public health.

Career Highlights

Rongshi Li has worked with esteemed organizations such as the H. Lee Moffitt Cancer Center and Research Institute, Inc. and Chongqing Zein Pharmaceutical Co., Ltd. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of his notable coworkers include Yan Liu and Said M Sebti, who have played a role in advancing his research initiatives. Their collaborative efforts have further enhanced the impact of his inventions.

Conclusion

Rongshi Li's innovative work in developing pyrrolomycin derivatives exemplifies his commitment to addressing critical health challenges. His contributions continue to pave the way for advancements in medical treatments and therapies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…